Abbott publishes clinical data for Parkinson’s therapy LCIG

Abbott has published data from a number of clinical studies revealing insights into the safety and effectiveness of an investigational Parkinson's disease treatment.

The company attended this week's International Congress of Parkinson's Disease and Movement Disorders in Dublin to announce results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its treatment for advanced Parkinson's.

Results from the second interim analysis of a long-term safety and tolerability trial were positive, with the majority of adverse events proving mild to moderate, transient and resolved over time.

Meanwhile, secondary endpoint analysis from a phase III pivotal trial indicated that LCIG can offer benefits compared to standard levodopa-carbidopa immediate release tablets.

Dr Robert Lenz, divisional vice-president for global pharmaceutical research and development at Abbott, said: "Obtaining pivotal and supportive clinical data is a critical stage in the overall development process of LCIG and further supports our efforts to develop LCIG for advanced Parkinson's disease patients."

This comes after the firm highlighted positive data on LCIG at the American Academy of Neurology annual meeting in April 2012.